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Abstract
Background: Chondrosarcoma is a malignant cartilage forming bone tumour for which no effective systemic
treatment is available. Previous studies illustrate the need for a better understanding of the role of the IGF pathway
in chondrosarcoma to determine if it can be a target for therapy, which was therefore explored in this study.
Methods: Expression of mediators of IGF1R signalling and phosphorylation status of IRS1 was determined in
chondrosarcoma cell lines by qRT-PCR and western blot. The effect of activation and inhibition of IGF1R signalling
on downstream targets was assessed by western blot. Ten chondrosarcoma cell lines were treated with OSI-906
(IGF1R and IR dual inhibitor) after which cell proliferation and migration were determined by a viability assay and
the xCELLigence system, respectively. In addition, four chondrosarcoma cell lines were treated with a combination
of doxorubicin and OSI-906. By immunohistochemistry, IGF1R expression levels were determined in tissue
microarrays of 187 cartilage tumours and ten paraffin embedded cell lines.
Results: Mediators of IGF1R signalling are heterogeneously expressed and phosphorylated IRS1 was detected in
67 % of the tested chondrosarcoma cell lines, suggesting that IGF1R signalling is active in a subset of
chondrosarcoma cell lines. In the cell lines with phosphorylated IRS1, inhibition of IGF1R signalling decreased
phosphorylated Akt levels and increased IGF1R expression, but it did not influence MAPK or S6 activity. In line with
these findings, treatment with IGF1R/IR inhibitors did not impact proliferation or migration in any of the
chondrosarcoma cell lines, even upon stimulation with IGF1. Although synergistic effects of IGF1R/IR inhibition with
doxorubicin are described for other cancers, our results demonstrate that this was not the case for
chondrosarcoma. In addition, we found minimal IGF1R expression in primary tumours in contrast to the high
expression detected in chondrosarcoma cell lines, even if both were derived from the same tumour, suggesting
that in vitro culturing upregulates IGF1R expression.
Conclusions: The results from this study indicate that the IGF pathway is not essential for chondrosarcoma growth,
migration or chemoresistance. Furthermore, IGF1R is only minimally expressed in chondrosarcoma primary tumours.
Therefore, the IGF pathway is not expected to be an effective therapeutic target for chondrosarcoma of bone.
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Background
Chondrosarcoma is the second most common primary
bone malignancy in humans [1] and represents a hetero-
geneous collection of cartilage forming tumours with
different outcomes depending on subtype and histo-
logical grade. Conventional central chondrosarcoma,
arising centrally in the medulla of bone, accounts for
~85 % of the cases and can be histologically divided into
3 grades [1]. Sixty-one percent of these tumours are
classified as atypical cartilage tumour (ACT) (previously
known as grade I), for which first line treatment is curet-
tage with local adjuvant treatment, resulting in a 5 year
survival rate of 83 %. Grade II (36 %) and grade III (3 %)
tumours are more prone to metastasize and have a com-
bined 5 year survival rate of 53 % [1–3]. These tumours
are treated with en bloc resection. Dedifferentiated
chondrosarcoma is a highly malignant variant with an
overall survival rate of 7 ~ 24 % [4]. Mesenchymal chon-
drosarcoma is a rare aggressive subtype, in which distant
metastasis can be identified even after 20 years [5]. It
has a 10 year survival rate between 44 and 54 % [6, 7].
Chondrosarcoma patients with unresectable disease, due
to tumour location, tumour size or extensive metastatic
disease, have a 5 year survival of only 2 % [8]. Although
chondrosarcoma is known for its resistance to chemo-
and radiotherapy, it was recently described that patients
with inoperable disease treated with doxorubicin-based
chemotherapy have a 3 year survival rate of 26 % versus
8 % in patients who did not receive systemic treatment
[8] and chemotherapy sensitivity differed between the
chondrosarcoma subtypes [9]. However, it is clear that
overall efficacy of chemotherapy is limited. So far, the dis-
covered genetic alterations and pathways involved in
chondrosarcoma (reviewed in [10] and [11]) have not re-
sulted in new treatment regimes. Therefore, further unrav-
elling of critical signalling pathways in chondrosarcoma is
essential to identify new therapeutic targets.
One pathway which has been implicated in chondro-
sarcoma proliferation is the IGF pathway. The IGF path-
way has two closely related ligands: IGF1 and IGF2 [12].
When a ligand binds to the IGF1 receptor (IGF1R), this
receptor forms homodimers or hybrid receptors with the
insulin receptor (IR). The resulting autophosphorylation
of the receptor recruits the insulin receptor substrate
(IRS) to the membrane causing subsequent downstream
activation of the PI3K/Akt/mTOR pathway and the Ras/
Raf/MEK signalling pathway, which are known to be
driver pathways in cancer [12]. IGF2R functions to de-
crease the availability of IGF2 to IGF1R [12].
IGF1R can be the upstream receptor that is respon-
sible for the well known activation of the PI3K/Akt/
mTOR pathway, the Src-pathway and the Ras/Raf/MEK
pathway in (a subset of ) chondrosarcoma cell lines and
primary cultures [13–17]. In a heterogeneous group of
sarcoma patients, a combination of an IGF1R antibody
and mTOR inhibitor has been shown to have clinical ac-
tivity but the level of IGF1R expression was not predict-
ive for response [18]. Takigawa et al. demonstrated that
cells of a clonal human chondrosarcoma-derived chon-
drocyte cell line produce IGF ligands and express IGF1R
and IGF2R [19]. Seong et al. and Matsumari et al. described
that IGF1 increases cell proliferation in a Swarm-rat chon-
drosarcoma model [20, 21]. Interestingly, Ho et al. de-
scribed that IGF binding protein 3 (IGFBP3), which binds
the IGF ligands thereby inhibiting their interaction with the
IGF receptors, decreases with increasing histological grade
of chondrosarcoma [22]. In addition, Wu et al. demon-
strated that IGF1 induced migration of chondrosarcoma
cell lines which could be blocked by an IGF1R antibody
[23]. Recently, functional profiling of receptor tyrosine
kinases in chondrosarcomas revealed active IGF1R signal-
ling in one out of five chondrosarcoma cell lines [13].
These above mentioned studies illustrate the need for a
better understanding of the role of IGF1R signalling in
chondrosarcoma to determine if it is a convincing target for
therapy. Because chondrosarcoma is a very heterogenous
disease, it is possible that the IGF1R directed therapy is only
effective in a subset of patients. Hence, we used our large
chondrosarcoma cell line panel, including three grade 2
and three grade 3 conventional chondrosarcomas, three
dedifferentiated chondrosarcomas and one mesenchymal
chondrosarcoma cell line. We analyzed expression levels
of IGF1R and other important mediators of IGF1R
signalling and determined the effect of IGF1R inhibi-
tors. Our results indicate that the IGF pathway is not
important for chondrosarcoma growth as IGF1R in-
hibition did not demonstrably impact chondrosarcoma
cell line proliferation, migration and chemoresistance.
In addition, IGF1R expression is low/absent in chon-
drosarcoma primary tumours in contrast to chondro-
sarcoma cell lines. This illustrates that there is
limited preclinical rationale for using IGF1R inhibitors
for the treatment of chondrosarcoma of bone.
Methods
Compounds
The IGF1R inhibitors OSI-906, NVP-ADW742 and
GSK1838705A were purchased from Selleck Chemicals
LCC (see Additional file 1: Table S1 for properties) and dis-
solved in DMSO in a concentration of 10 mM. The IGF1R
inhibitors were tested in concentrations up to 1 μM as it
was demonstrated previously that higher concentrations
lead to an aspecific toxic response [24]. Recombinant
human IGF1 (PeproTech) was used in a concentration of
50 ng/ml [25]. Doxorubicin was obtained from the in-
house hospital pharmacy in a 0.9 % NaCl solution, and used
in a concentration range of 1–100 nM.
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Cell culture
The conventional chondrosarcoma cell lines JJ012 [26],
SW1353 (ATCC), CH2879 [27], OUMS27 [28], L835 [29]
and CH3573 [30], as well as the dedifferentiated chondrosar-
coma cell lines L3252B [29], NDCS1 [31], and L2975 [29]
were cultured in RPMI 1640 (Gibco, Invitrogen) supple-
mented with 1 % Glutamax (Gibco 35050, Invitrogen), 1 %
penicillin/streptomycin (PS) (100U/mL) (Gibco, Invitrogen)
and 10 % (JJ012, SW1353, CH2879, NDCS1, L2975) or
20 % (L835, L3252B, OUMS27, CH3573) heat-inactivated
Fetal Bovine Serum (FBS) (F7524, Sigma-Aldrich). MCS170
(Mesenchymal chondrosarcoma) and TC-32 (Ewing Sar-
coma, [32]) were cultured in IMDM (Gibco, Invitrogen)
with 1 % PS with respectively 15 and 10 % FBS. The cells
were grown at 37 °C with 5 % CO2 in a humidified incuba-
tor. Mycoplasma tests were performed regularly. Identity of
cell lines was confirmed using STR profiling with the CELL
ID™ system (Promega Benelux BV).
qRT-PCR
RNA isolation and cDNA synthesis was performed as
described [33]. To determine the expression levels of
IGF1, IGF1R, IGF2, IGF2R, IGFBP3 and IR, a standard
quantitative reverse transcriptase PCR (qRT-PCR) was
performed as described previously [34]. Primers
(Additional file 2: Table S2) were designed using primer3
software (http://bioinfo.ut.ee/primer3/). To correct for
the amount of cDNA input, gene expression levels were
normalized using the expression levels of CYPa and
CPSF6 [35, 36]. ΔΔCq values below 0.01 were consid-
ered negative. All qRT-PCRs were optimized on control
tissue as indicated in Additional file 2: Table S2.
Immunoprecipitation and Western Blotting
Western blotting was performed as described previously
[14]. Per sample, 20 μg of protein was loaded on SDS-
PAGE gels. Rabbit antibodies against IGF1R (#3018), IR
(#3025),IRS1 (#2382) and Phospho-S6 Ribosomal Protein
(Ser235/236) (2 F9) (#4856) all diluted 1:1000, were ob-
tained from Cell Signaling. Phospho-Akt (Ser473) (#9271),
diluted 1:2000 was also obtained from Cell Signaling.
Rabbit polyclonal antibody against phospho-IRS1 (Y612,
1:1000) was purchased from Biosource, Invitrogen. Mono-
clonal Anti-MAP Kinase, Activated (Diphosphorylated
ERK-1&2) was obtained from Sigma (M8159) and diluted
1:2000. A mouse monoclonal antibody against α-tubulin
(1:3000) (Abcam) was used as a loading control. Second-
ary antibodies were horseradish peroxidase (HRP) conju-
gated polyclonal goat-anti-rabbit IgG for components for
IGF1R, IR, IRS1, phospho-IRS1, pAkt and pS6, and HRP
conjugated polyclonal goat-anti-mouse for α-tubulin and
diphos. ERK-1&2 (both 1:3000, BD Transduction Labora-
tories). Immunoprecipitation (IP) for IRS1 was performed
according to the manufacturer’s instruction. In short, cells
were harvested at ±80 % confluence using the Cell lysis
buffer (Cell Signaling) to which the PhosSTOP (REF
04906837001) and the Protease Inhibitor Cocktail Tablets
(REF 11697498001) were added (Roche). The IRS1 anti-
body (1:50) was added to 200 μl lysate at 1 mg/ml and ro-
tated over night at 4 °C, followed by 30 min incubation
with 40 μl protein A magnetic beads (Cell Signaling). After
washing using a magnetic separation rack, the pellet was
suspended in 3x SDS sample buffer (containing 2-
Mercaptoethanol). The sample was loaded on an SDS-
PAGE gel and western blotting was performed as described
above. TC-32 was used to optimize the protocol and was
included as a positive control.
Proliferation assay
In all cell viability experiments, the cell lines were plated
in triplicate at a density of 3000 to 10000 cells per well
depending on the growth rate. For the positive control
(Ewing sarcoma cell line TC-32) the 96 well plates were
coated with gelatine. After the cells were allowed to ad-
here overnight, the IGF1R inhibitors were added in their
corresponding concentrations. In addition, we deter-
mined the effect of OSI-906 when IGF1 (50 ng/ml) was
added to the medium. For the combination treatment of
doxorubicin and OSI-906, both inhibitors were added at
the same time. Because JJ012 and SW1353 are relatively
more sensitive to doxorubicin, JJ012 and SW1353 were
treated with 0, 1 nM, 10 nM or 100 nM while CH2879
and OUMS27 were treated with 0, 10 nM, 50 nM and
100 nM doxorubicin. These concentrations of doxorubi-
cin were combined with DMSO, 0.1 μM, 0.5 μM or
1 μM OSI-906. After 72 h of incubation, cell viability was
measured using the WST-1 reagent (Roche) (single treat-
ment with OSI-906) or PrestoBlue Cell Viability Reagent
(Promega Benelux BV) (single treatment with NVP-
ADW742 and GSK1838705A and combinations with
IGF1 and doxorubicin) according to the manufacturer’s
instructions. Colorimetric values in the plates were subse-
quently measured using a Wallac 1420 VICTOR2 (Perkin
Elmer). Data were analysed in Graphpad Prism 5.0
(www.graphpad.com). The results shown are representa-
tive results from at least three independent experiments.
Migration assay
The real-time cell analyser xCELLigence system (Roche)
based on cell-electrode subtract impedance detection
technology [37] was used to study the effect of IGF1R/IR
inhibition on migration as previously described [16]. In
short, cell lines were added at a density of 80.000 per
well in the upper chamber of the Cell Invasion and
Migration (CIM) plates in serum-free RPMI medium
containing 0, 100 nM or 1 μM OSI-906. The lower
chambers were filled with RPMI medium supplemented
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with 20 % FBS. The software calculated the Cell index,
which was set at 1.0 migration at the last measurement.
Immunohistochemistry on tissue microarrays
The specificities of two IGF1R antibodies (#3018 and
#3027, Cell Signaling) were compared by western blot
(as described above) and immunohistochemistry on
colon tissue (as described in [38]). The most specific
antibody was selected to determine the IGF1R expression
in 5 enchondromas, 7 osteochondromas, 71 central con-
ventional chondrosarcomas, 34 peripheral conventional
chondrosarcomas, 32 dedifferentiated chondrosarcomas,
18 mesenchymal chondrosarcomas and 20 clear cell
chondrosarcomas by using previously constructed and de-
scribed tissue microarrays (TMAs) [16, 39]. Slides were
scored by an experienced pathologist (AHGC) as either
positive or negative.
Results
IGF pathway members are expressed in a subset of
chondrosarcoma cell lines
Using qRT-PCR analyses, we demonstrate that all cell
lines express the receptors IGF1R, IGF2R and IR
(Fig. 1a). However, expression levels are highly variable
as L835, OUMS27 and NDCS1 have a relatively high ex-
pression of the three receptors as compared to the other
cell lines. For the IGF1R and the IR, we correlated the
mRNA expression levels to levels of protein expression
(Fig. 1b). mRNA expression of the ligand IGF1 is re-
stricted to four out of ten chondrosarcoma cell lines,
with the highest expression in L835. Strikingly, IGF2 ex-
pression in OUMS27 is very high, comparable to the ex-
pression levels in a human placenta (data not shown).
IGFBP3 mRNA expression is detected in 8 out of 10
chondrosarcoma cell lines. In addition, western blot ana-
lyses revealed protein expression of IRS1 in all cell lines,
a
b c d
Fig. 1 a-b qRT-PCR and western blot analyses, respectively, reveal heterogeneous expression of IGF pathway members in chondrosarcoma cell
lines. c Immunoprecipitation with IRS1 followed by a western blot for phospho-IRS1 reveals pathway activity in two out of three chondrosarcoma
cell lines tested. d Evaluation of IGF1R downstream targets reveals an effect of OSI-906 on IGF1R and pAkt but not on pS6 and disphosphorylated
ERK-1&2. Cell lines were treated for 72 hours with DMSO, 1 μM OSI-906 and/or 50 ng/ml IGF1
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although expression levels are again variable amongst
the different cell lines (Fig. 1b).
IGF1R signalling is active in a subset of chondrosarcoma
cell lines
To determine IGF pathway activity, the phosphorylation
status of IRS1 was determined in three chondrosarcoma
cell lines. Immunoprecipitation for IRS1 followed by
western blot analyses with a phospo-IRS1 antibody re-
vealed the presence of phosphorylated IRS1 in JJ012 and
SW1353, but not in CH2879 (Fig. 1c). This demonstrates
that IGF1R signalling is active in a subset of chondrosar-
coma cell lines. Furthermore, only in the cell lines in
which phosphorylated IRS1 was detected, phosphory-
lated Akt levels were decreased and IGF1R levels were
increased by OSI-906 (dual IGF1R and IR inhibitor)
treatment (Fig. 1d). However, phosphorylated S6, located
downstream of Akt, and diphosphorylated ERK-1&2
were unaffected, suggesting that activity of the down-
stream targets is not dependent on IGF1R signalling.
Viability and migration of chondrosarcoma cell lines is
not affected by IGF1R inhibition
Treating our full chondrosarcoma cell line panel for
72 h with concentrations from 0.01 to 1000 nM of OSI-
906 revealed that chondrosarcoma cell viability was not
affected by inhibition of the IGF pathway, whereas the
positive control cell line TC-32 (Ewing sarcoma) showed
dose-dependent decrease of cell viability (Fig. 2a). Fur-
thermore, addition of IGF1 to the medium did not in-
crease cell proliferation (Additional file 3: Figure S1) nor
sensitivity to OSI-906 (Fig. 2b) in three chondrosarcoma
cell lines tested. In addition, four chondrosarcoma cell
lines and the Ewing sarcoma cell line were treated with
two other IGF1R/IR inhibitors (NVP-ADW742 and
GSK1838705A) to determine if alternative targeting
showed similar effects on cell viability (Fig. 2c and d).
Indeed, the results were highly comparable, demonstrat-
ing that the IGF pathway is not essential for chondrosar-
coma cell viability.
By adding OSI-906 to the upper chamber of the CIM
plates (xCELLigence), we demonstrated that IGF1R sig-
nalling was not essential for the migration of JJ012,
SW1353, CH2879 and OUMS27 (Fig. 3). To exclude the
possibility that the absence of an effect of OSI-906 on
chondrosarcoma cell migration was caused by an insuffi-
cient treatment duration, the cell lines were treated with
1 μM OSI-906 for 72 h before the onset of the experi-
ment in one experimental condition. However, even after
this pretreatment, chondrosarcoma cell line migration
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Fig. 2 Relative cell viability of 72 hours of treatment with IGF1R/IR inhibitors. a-b OSI-906 does not inhibit chondrosarcoma cell viability, even in
the presence of IGF1. c-d IGF1R inhibitors NVP-ADW742 and GSK1838705A do not inhibit chondrosarcoma cell viability
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was not influenced by IGF1R/IR inhibition, illustrating
that the IGF pathway does not play a role in chondrosar-
coma cell migration.
The IGF pathway is not involved in chondrosarcoma
chemoresistance
Because IGF1R signalling has been implicated in che-
moresistance [40], four chondrosarcoma cell lines were
treated with a combination of OSI-906 and doxorubicin.
Although doxorubicin inhibited cell viability in a dose
dependent manner, IGF1R/IR inhibition did not increase
this cytotoxicity in any of the cell lines (Fig. 4). This in-
dicates that the IGF pathway is not involved in chondro-
sarcoma chemoresistance.
IGF1R is not strongly expressed in uncultured cartilage
tumours
To elucidate the discrepancy between the observed protein
expression of IGF1R in cell lines and the absence of an effect
of IGF pathway inhibition, we assessed IGF1R expression in
clinical tumour samples versus cell lines that were formalin-
fixed and paraffin-embedded (FFPE). IGF1R antibody #3018
was selected for these immunohistochemical stainings as
both the positive immunohistochemical control and the
control western blot demonstrated its high specificity
compared to the IGF1R antibody #3027 (Additional file 4:
Figure S2). Immunohistochemistry confirmed the western
blot evidence of IGF1R expression (Fig. 1b), with membran-
ous expression of IGF1R shown in ten cell lines, and IGF1R
expression levels were comparable in western blot and im-
munohistochemistry evaluations (Fig. 5a-b). In contrast, the
primary tumours were either completely negative (66 %) or
showed very weak staining (34 %) for IGF1R (Fig. 5c,
Table 1). To exclude the possibility that the discrepancy be-
tween the primary tumours and the cell lines was due to tis-
sue handing procedures, we included a colon tissue sample
that was decalcified by 20 % formic acid for 2 days which
stained positive thereby excluding an effect of the decalcifi-
cation procedure (Additional file 5: Figure S3). To further
study the difference in IGF1R expression between primary
tumours and cell lines, we stained the primary tumours
corresponding to the cell lines L835 [29], CH2879 [27],
L3252B [29] and L2975 [29]. Strikingly, the primary tu-
mours were either completely negative (L835, CH2879) or
showed weak staining (L3252B, L2975) for IGF1R (Fig. 5d,
Additional file 6: Figure S4). This suggests that chondrosar-
coma cells upregulate IGF1R upon prolonged culturing.
Discussion
The aim of this study was to investigate whether the IGF
pathway is a suitable target for therapy in chondrosar-
coma. Heterogeneous expression of IGF1R, IR, IGF2R,
IGF1, IGF2, IRS1 and IGFBP3 was seen, both at the
mRNA and protein levels, in chondrosarcoma cell lines.
This indicates that essential IGF pathway components
are present in cultured chondrosarcoma cells. Further-
more, detection of phosphorylated IRS1 in two out of
three chondrosarcoma cell lines demonstrates that the
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Fig. 3 OSI-906 does not inhibit migration of four chondrosarcoma cell lines. 72H OSI 1 μM: cells were treated for 72 hours with OSI-906 before
experimental onset
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IGF pathway is active in a subset of chondrosarcoma cell
lines. In the cell lines with phosphorylated IRS1, IGF
pathway inhibition decreased phosphorylated Akt levels
and increased IGF1R expression; the latter suggests acti-
vation of a feedback loop, which is further supported by
the downregulation of IGF1R expression by IGF1 treat-
ment. However, this did not influence the amount of phos-
phorylated S6, which is located further downstream in the
PI3K/Akt/mTOR pathway. Furthermore, the activated
MAPK levels were not affected by IGF pathway stimulation
or inhibition, demonstrating that activity of the down-
stream targets is not dependent on IGF1R signalling.
In line with these findings, we demonstrate that
despite activity of the pathway, IGF1R signalling is not
essential for chondrosarcoma cell survival. Treatment
with three different IGF1R/IR inhibitors does not have
an effect on chondrosarcoma cell viability, irrespective
of apparent pathway activity and stimulation with IGF1.
Chondrosarcoma cell line OUMS27 was previously
shown to be sensitive to IGF1R/IR inhibition by Zhang
et al. [13]. It is difficult to explain the discrepancy with
the current study, as OSI-906 is a derivate of the IGF1R
inhibitor used by Zang et al. with similar target potency
[41]. Moreover, we performed these assays at multiple
cell densities, passage numbers and IGF1R/IR inhibitors
(data not shown).
IGF1R signalling is involved in resistance to cytotoxic
drugs in certain cancers [40]. Since chondrosarcoma is
resistant to chemotherapy, we explored a possible role of
the IGF1R/IR pathway in chemoresistance. Doxorubicin
reduced cell viability in a dose dependent manner; how-
ever, OSI-906 did not further inhibit cell viability in this
cell line model. These results do not support a key role
of the IGF pathway in chondrosarcoma cell survival and
chemoresistance.
Our study could not confirm a role for the IGF pathway
in chondrosarcoma cell migration. In contrast to the study
from Wu et al., showing that IGF1 induced chondrosar-
coma migration was inhibited by an IGF1R antibody [23],
we chose not to pretreat the chondrosarcoma cells with
IGF1 and not to use medium supplemented with IGF1
only as chemoattractant, thereby better mimicking the in
vivo situation. These experimental differences might ex-
plain the difference in our findings.
Strikingly, we detected high expression of the IGF1R
in chondrosarcoma cell lines compared to primary tu-
mours. Moreover, we show that each of four patients
with matched cell lines and primary tumours had strong
Fig. 4 Relative cell viability after 72 hours of combination treatment with OSI-906 and Doxorubicin. OSI-906 does not sensitize the cells to doxorubicin
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membranous IGF1R expression in the cultured cells
compared to absent or very weak expression in the cor-
responding primary tumour. The finding that cell lines
are insensitive to IGF1R inhibition despite their high
IGF1R expression is in line with the results from the
study by Schwartz et al., which described absence of a
correlation between IGF1R expression levels and respon-
siveness to an IGF1R targeting antibody [18]. This series
included 38 chondrosarcomas of which 53 % had immu-
nohistochemical staining with an IGF1R antibody [18].
Therefore, we did not anticipate to find weak (34 %) or no
expression (66 %) in our cartilage tumour series. The dis-
crepancy between our results and the study from Schwartz
et al. can likely be explained by use of another antibody.
Lack of reproducibility is a well described phenomenon in
preclinical studies with antibodies [42, 43]. Our study
further suggests that IGF1R expression is lower in clear
cell chondrosarcoma and mesenchymal chondrosarcoma
compared to the other cartilage tumours. However, as
the staining is very weak in the samples scored positive
and IGF1R expression levels do not correlate with re-
sponsiveness to IGF1R targeting antibodies, we do not
think this difference in IGF1R expression has clinical sig-
nificance. Furthermore, we did not see a difference in
sensitivity to IGF1R inhibition between the mesenchy-
mal, dedifferentiated and conventional chondrosarcoma
cell lines included in this study.
Increased activity of the IGF pathway is implicated in
several other cancers [12] including other bone tumours
[44]. In Ewing sarcoma, IGF binding protein 3 (IGFBP3)
is downregulated by the EWSR1-FLI1 fusion gene [45],
Table 1 Immunohistochemistry demonstrates only weak IGF1R
expression in uncultured cartilage tumours
Diagnose Weak IGF1R positivity
Enchondroma 3/5 (60 %)
Osteochondroma 2/7 (29 %)
Central Conventional chondrosarcoma 32/71 (45 %)
Grade I 8/28 (29 %)
Grade II 15/29 (51 %)
Grade III 9/14 (64 %)
Peripheral Conventional chondrosarcoma 14/34 (41 %)
Grade I 8/21 (38 %)
Grade II 5/10 (50 %)
Grade III 1/3 (33 %)
Dedifferentiated chondrosarcoma 11/32 (34 %)
Mesenchymal chondrosarcoma 0/18 (0 %)
Clear cell chondrosarcoma 1/20 (5 %)
Total 63/187 (34 %)
ba
dc
50 µm
50 µm
50 µm
50 µm
Fig. 5 IGF1R expression is high in chondrosarcoma cell lines but low in primary tumours. a IGF1R expression in chondrosarcoma cell line JJ012.
b and d IGF1R expression in L835 cell line and primary tumour, respectively. c a conventional chondrosarcoma sample that was classified as weak
IGF1R staining. Black bars represent 50 μm
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activating the IGF pathway [46]. Recently, aberrant ex-
pression of IGF pathway members was described in
osteosarcomas and OSI-906, a dual inhibitor of the
IGF1R and the IR, inhibited proliferation in 3 out of 4
osteosarcoma cell lines with IC50 values within the
therapeutic range [24].
Clinical trials to test the safety and efficacy of IGF1R
antibodies, sometimes in combination with an mTOR
inhibitor, have been performed in sarcoma patients [47],
but only two trials enrolled chondrosarcoma patients
[18, 44]. In the study described by Olmos et al. one myx-
oid chondrosarcoma was included, which showed a
small decrease in tumour size upon IGF1R inhibition
[44]. It is unclear whether this was an extraskeletal myx-
oid chondrosarcoma or a chondrosarcoma of bone. In
addition, 1 of 17 chondrosarcoma patients showed par-
tial response to Cixutumumab (IGF1R antibody) and
Temsirolimus (mTOR inhibitor), as described by
Schwarz et al. [18]. In future studies, dual inhibitors of
both the IGF1R and the IR are preferably chosen be-
cause it has been shown in osteoblasts [48] and Ewing
sarcoma cells [49] that cells can circumvent inhibition of
IGF1R by increasing IR signalling.
Conclusions
In summary, the results of this study demonstrate that al-
though chondrosarcoma cell lines have high IGF1R expres-
sion and activation of downstream targets, inhibition of
IGF1R/IR signalling does not affect chondrosarcoma prolifer-
ation, migration and chemoresistance. Therefore, we conclude
that there is no convincing preclinical rationale for using
IGF1R/IR inhibitors in the treatment of chondrosarcoma.
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